Jim Gilligan
President & Chief Scientific Officer Entropy Neurodynamics (formerly Tryp Therapeutics)
Dr. Gilligan has a deep history of drug development with a background in pharmacology, with an initial focus on the development of peptide-based therapeutics, rDNA product development and more recently psychedelic molecules. His areas of clinical research include: musculoskeletal diseases, cardiovascular disease, pain, endocrine & metabolic diseases and psychedelic assisted psychotherapy.
Jim has co-founded and helped lead several biopharma and bio-tech companies, including Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. Jim also has an MBA in International business and has executed numerous feasibility and licensing deals within the pharmaceutical industry, working frequently with investment bankers, venture capitalists, and brokers.
He is currently President and CSO at Tryp Therapeutics (DBA Entropy Neurodynamics) developing an IV infusion of psilocin the active metabolite of psilocybin to support psychedelic assisted therapy to address unmet medical needs. Tryp completed 3 early-stage clinical studies in the US exploring the clinical utility of psychedelic assisted therapy in patients with Binge Eating Disorder, Fibromyalgia and IBS. Tryp is developing TRP:8803 a 2-phase IV infusion of psilocin, the active metabolite of psilocybin. TRP:8803 is comprised of a loading dose to achieve a target blood level of psilocin and a maintenance dose that allows for controlling the duration of the psychedelic experience. TRP:8803 is currently being evaluated in patients with BED as well as a Basket Study investigating 8 independent indications.
Seminars
- Distinguishing nociplastic pain from neuropathic pain and exploring the role of maladaptive neuroplasticity in sustaining chronic pain states
- Reviewing emerging clinical data on psychedelic assisted therapy in fibromyalgia, and IBS, including changes in functional outcomes and pain severity
- Evaluating neuroimaging and electrophysiological evidence, including fMRI and EEG biomarkers, to understand how psilocin may modulate central pain processing
- Discussing the translational path from early clinical findings with oral psilocybin, transitioning to an IV infusion of psilocin (TRP:8803) and meeting with FDA to help develop the regulatory strategy for future development opportunities across chronic pain indications
